SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*
上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

VOLUNTARY ANNOUNCEMENT – NEW INDICATIONS OF TUOYI® AND MINDEWEI* (民得維®) HAVE BEEN INCLUDED IN THE NEW EDITION OF THE NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the "**Company**") on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 13 December 2023.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the Company's product Toripalimab Injection (trade name: TUOYI®, product code: JS001) and Deuremidevir Hydrobromide Tablets (trade name: MINDEWEI* (民得維®), product code: VV116/JT001) were successfully included in Category B of the National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (Year 2023) (the "**NRDL**") upon negotiations. In particular, TUOYI® has 3 new indications included, all six approved indications of TUOYI® in China are included in the NRDL currently, and TUOYI® is the only anti-PD-1 monoclonal antibody included in the NRDL for the treatment of melanoma. The indication of MINDEWEI* (民得維®) for adult patients with mild to moderate coronavirus disease 2019 ("**COVID-19**") is officially included in the NRDL for the first time.

ABOUT TUOYI®

Drug name: Toripalimab Injection
Classification of registration: Therapeutic biological product
Class of drug: Antineoplastic drug and immune modulator – monoclonal antibody
Class of medical insurance: Category B
Dosage form: Injection

Indications: 1. Treatment for unresectable or metastatic melanoma after failure of standard systemic therapy; 2. Treatment for locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy; 3. Treatment for recurrent/metastatic nasopharyngeal carcinoma ("**NPC**") after failure of at least two lines of prior systemic therapy; 4. First-line treatment for patients with locally recurrent or metastatic NPC; 5. First-line treatment for patients with unresectable locally advanced/recurrent or metastatic esophageal squamous cell carcinoma ("**ESCC**"); 6. First-line treatment for patients with EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
Validity period: From 1 January 2024 to 31 December 2025

Toripalimab is the first domestic anti-PD-1 monoclonal antibody approved for marketing in China, and has won the "Chinese Patent Gold Award (中國專利金獎)", the top award in China's patent field. Over forty company-sponsored clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States, Southeast Asia and Europe. Ongoing or completed pivotal clinical studies evaluating the safety and efficacy of toripalimab cover a broad range of tumor types. As of the date of this announcement, there are six approved indications for toripalimab in China. In December 2020, toripalimab injection was successfully negotiated into the NRDL (2020 edition) for the first time. At present, six indications are included in the NRDL, being the only anti-PD-1 monoclonal antibody in the NRDL for the treatment of melanoma.

In terms of international registration activities, toripalimab was approved for marketing as the first nasopharyngeal cancer drug in the United States in October 2023. In addition, the European Medicines Agency (EMA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) accepted the marketing authorization application (MAA) for toripalimab in combination with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC, and toripalimab in combination with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC. The Australia Therapeutic Goods Administration (TGA) accepted the new chemical entity application for toripalimab in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and for toripalimab, as a single agent, for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy.

ABOUT MINDEWEI* (民得維®)

Drug name: Deuremidevir Hydrobromide Tablets (氫溴酸氘瑞米德韋片)
Classification of registration: Type 1 of chemical drug
Class of drug: Systematic antiviral drugs-other antiviral drugs
Class of medical insurance: Category B
Dosage form: Tablets
Indication: Adult patients with mild to moderate COVID-19.
Validity period: From 1 January 2024 to 31 December 2025

MINDEWEI* (民得維®) is a new oral nucleoside analog antiviral drug, which can be non-covalently bound to the active center of RNA-dependent RNA polymerase ("**RdRp**") of SARS-CoV-2 in the form of nucleoside triphosphate, directly inhibiting the activity of RdRp of the virus and blocking the replication of virus, thus realizing the antiviral effect. Preclinical studies have shown that MINDEWEI* (民得維®) exhibited significant antiviral effects against both the original COVID-19 strain and mutant strains, including Omicron, and exhibited no genetic toxicity. The results of the two Phase III clinical studies showed that MINDEWEI* (民得維®) significantly accelerated the recovery of adult patients with mild to moderate COVID-19 compared to placebo and was not inferior to the Nematvir/Ritonavir combination drug. MINDEWEI* (民得維®) was jointly developed by Shanghai Institute of Materia Medica, Chinese Academy of Sciences* (中國科學院上海藥物研究所), Wuhan Institute of Virology, Chinese Academy of Sciences* (中國科學院武漢病毒研究所), Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences* (中國科學院新疆理化技術研究所), Central Asian Center of Drug Discovery and Development of Chinese Academy of Sciences* (中國科學院中亞藥物研發中心)/ China-Uzbekistan Medicine Technical Park (the Belt and Road Joint Laboratory of the Ministry of Science and Technology)* (中烏醫藥科技城(科技部"一帶一路"聯合實驗室)), Lingang Laboratory* (臨港實驗室), Vigonvita Life Sciences Co., Ltd.* (蘇州旺山旺水生物醫藥有限公司) and the Company.

IMPACTS ON THE COMPANY AND RISK WARNING

The inclusion of TUOYI® and MINDEWEI* (民得維®) in the NRDL demonstrated the National Healthcare Security Administration's (the "**NHSA**") recognition of the clinical value, benefit to patients and novelty of the above drugs, highlighting the state's emphasis on and support for the R&D and industrialization of drugs by local innovative pharmaceutical enterprises. All six approved indications of TUOYI® are included in the NRDL, which will further expand the scope of patients benefiting from different tumor types, and reduce the burden of medical treatment for patients and their families. The official inclusion of MINDEWEI* (民得維®) in the NRDL for the first time is of great significance to the work on national long-term public health prevention and control, as well as public health.

The results of NRDL negotiations will help the Company to further improve the affordability and accessibility of the aforesaid drugs to patients, which will be conducive to further promoting the marketing of the drugs and enhancing the sales scale, and will have a positive impact on the long-term development of the Company. The Company will actively work with relevant parties to implement the related medical insurance and reimbursement policies, promote the accessibility of the drugs to hospitals with continuous efforts, and expand the coverage of core markets and other markets, with a view to constantly enhancing the accessibility of medicines to patients. Details of medical insurance reimbursement and other relevant information shall be subject to the information published by the NHSA and other relevant government departments. Investors are advised to make cautious decisions and pay careful attention to investment risks.

By Order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 13 December 2023

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun and Dr. Wang Gang as executive Directors; Dr. Feng Hui, Mr. Tang Yi and Dr. Li Xin as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* *For identification purpose only*